My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
A brief recap of Diagnostics news the week of Feb 1, 2019: Ambry Genetics, Quotient, Angle, PathAI, C2N Diagnostics, Interpace Diagnostics
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.